French startup luggage €2M to make most cancers medical trials extra accessible

Paris-based Klineo has raised €2mn for its AI platform that facilitates entry to most cancers medical trials.

Klineo’s platform connects docs and sufferers instantly with related medical trials. It offers trial search, contact with medical centres, in addition to real-time updates and notifications when a brand new medical trial matches the affected person’s standards.

The startup’s answer at present covers trials on pores and skin most cancers, breast most cancers, and lymphoma.

Klineo was based in 2021 by oncologist Dr Arnaud Bayle and two engineers, Thomas Peyresblanques and Nicolas Drizard.

The <3 of EU tech

The most recent rumblings from the EU tech scene, a narrative from our sensible ol’ founder Boris, and a few questionable AI artwork. It is free, each week, in your inbox. Join now!

The startup goals to speed up the inclusion of sufferers in medical trials, which play a key position in introducing novel and probably life-saving therapies, providing vital hope to people grappling with the sickness.

“At present, too few sufferers profit from a medical trial as a result of the seek for one is a really tedious course of,” Dr Arnaud Bayle stated in a press release.

According to the Cancer Research Institute, lower than 10% of most cancers sufferers who’re eligible for medical trials take part in a single. On the similar time, roughly 20% of clinical trials fail due to inadequate participation.

“[Our] answer lastly provides docs and sufferers, wherever they’re handled, the potential for simply discovering new therapeutic choices tailored to every scenario, and which finally permits medical analysis to progress,” Dr Bayle stated.

Klineo will use the brand new funding to cowl all varieties of most cancers trials in France by the top of 2024, beginning with lung most cancers. The startup can even improve its workforce and enhance its platform.

The French public funding financial institution BPI and a variety of enterprise angels participated within the spherical, which marked the corporate’s first fundraising try.

Sooner or later, Klineo goals to broaden its companies past France and embrace trials for different diseases, resembling uncommon and neurological ailments.